[ad_1]
The US Food and Drug Administration has published "FDA" A new warning for the drug "Multada" containing the active substance (Alimtuzumab) after reports of patients with stroke and problems of the mucous membrane of the arteries of the head and neck.
She noted"FDA" Most patients with these symptoms have been shown to have symptoms less than a day after receiving an initial dose of Lamartada three days after administration.
Says a specialist in multiple sclerosis "MS" The information is important for people with multiple sclerosis, but that does not mean that they should stop taking the medicine immediately.
"You always have to balance the risks and benefits of treatment versus the risk of the disease," said Dr. Assaf Harel, a neurosurgeon at Lenox Hill Hospital in New York. "For many patients, the drug is a truly effective treatment, The benefits can outweigh the potential risks for some patients.
In the interim, the Food and Drug Administration announced the imposition of a new warning regarding the risks associated with the prescription drug information and patient treatment guide.
Source link
